China’s controversial gene-editing scientist, He Jiankui, who created the world’s first genetically modified babies, continues to operate openly within the country’s rapidly expanding biotechnology sector. Despite serving a three-year prison sentence for deceiving medical authorities, the 41-year-old researcher is neither marginalized nor silenced; he actively discusses his work and asserts China’s readiness to embrace such advancements.
The Curious Case of Unfettered Freedom
He Jiankui’s continued presence in China’s biotech landscape is unusual, given the country’s strict censorship and control mechanisms. Although his passport remains seized, preventing international travel, he has become a vocal figure, boasting about his research and suggesting a growing acceptance of boundary-pushing scientists. This raises the question of why Chinese authorities have not fully suppressed him.
According to Benjamin Hurlbut, an associate professor at the University of Arizona, this apparent tolerance may be strategic. “In a period of increasing tension between China and the West… Dr. He is not seen as a liability, but is apparently seen as a potential asset.” This suggests that China views him as a symbol of its technological ambition, particularly in biotechnology.
A Growing Demand for Unconventional Research
During an interview in his Beijing apartment, provided with security by an undisclosed sponsor, He Jiankui claimed a rising demand within China for researchers willing to challenge conventional limits. This indicates that despite ethical concerns, China may be fostering an environment where radical scientific experimentation is encouraged, possibly as a means of accelerating progress and asserting dominance in the biotech field.
The fact that China tolerates He Jiankui’s continued presence suggests a calculated decision to leverage his notoriety and expertise for strategic advantage.
Ultimately, China’s handling of He Jiankui underscores its willingness to prioritize technological advancement over conventional ethical constraints, potentially signaling a shift in global biotechnology leadership.
